


## Accepted Manuscript

Title: Widespread use of measurable residual disease in acute myeloid leukemia practice

Authors: Zachary D. Epstein-Peterson, Sean M. Devlin, Eytan M. Stein, Elihu Estey, Martin S. Tallman



PII: S0145-2126(18)30041-9  
DOI: <https://doi.org/10.1016/j.leukres.2018.02.006>  
Reference: LR 5914

To appear in: *Leukemia Research*

Received date: 15-11-2017  
Revised date: 6-2-2018  
Accepted date: 9-2-2018

Please cite this article as: Epstein-Peterson Zachary D, Devlin Sean M, Stein Eytan M, Estey Elihu, Tallman Martin S. Widespread use of measurable residual disease in acute myeloid leukemia practice. *Leukemia Research* <https://doi.org/10.1016/j.leukres.2018.02.006>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: Widespread Use of Measurable Residual Disease in Acute Myeloid Leukemia Practice  
Running head: Minimal Residual Disease in Acute Myeloid Leukemia Survey

Authors: Zachary D. Epstein-Peterson MD<sup>a</sup>, Sean M. Devlin PhD<sup>b</sup>, Eytan M. Stein MD<sup>a,c,d</sup>, Elihu Estey MD<sup>e</sup>, Martin S. Tallman MD<sup>a,c,d</sup>

Affiliations:

<sup>a</sup>Department of Medicine, Memorial Sloan Kettering Cancer Center

<sup>b</sup>Department of Biostatistics, Memorial Sloan Kettering Cancer Center

<sup>c</sup>Division of Hematologic Oncology, Leukemia Service, Memorial Sloan Kettering Cancer Center

1275 York Ave, New York, NY, 10065, USA

<sup>d</sup>Department of Medicine, Weill Cornell Medical College, 1300 York Ave, New York, NY, 10065, USA

<sup>e</sup>Seattle Cancer Center Alliance, UW Box 358081, Mailstop G3-200, 825 Eastlake Ave E., Seattle, WA, 98109, USA

Email addresses:

Zachary D. Epstein-Peterson MD: epsteinz@mskcc.org

Sean M. Devlin PhD: devlins@mskcc.org

Eytan M. Stein MD: steine@mskcc.org

Elihu Estey MD: EEstey@seattlecca.org

Martin S. Tallman MD: tallmanm@mskcc.org

Corresponding author:

Martin S. Tallman, MD

Memorial Sloan Kettering Cancer Center

1275 York Avenue

New York, NY, 10065

TallmanM@mskcc.org

Telephone: 212-639-3842

Highlights

- Use of MRD among leukemia care providers in acute myeloid leukemia is common
- MRD is used frequently in estimating prognosis and in making treatment decisions
- More years of experience, female gender, and transplant practice predicted MRD use
- Nucleophosmin 1 was the most common target utilized in MRD testing
- Variations in MRD testing and management exist in contemporary practice

Abstract

Download English Version:

<https://daneshyari.com/en/article/8453364>

Download Persian Version:

<https://daneshyari.com/article/8453364>

[Daneshyari.com](https://daneshyari.com)